Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Lind Landström, Tove ^a   Varughese, Rosilin K ^a   Sundstrøm, Stein ^b   Torp, Sverre H ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Brain tumours; Diagnosis; Gliomas; Immunohistochemistry; Ki67 MIB 1; Prognosis; Survival

Indexed keywords

CELL CYCLE PROTEIN; KI 67 ANTIGEN; MCM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER STAGING; CELL PROLIFERATION; CHEMISTRY; CLASSIFICATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84876693261     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-67     Document Type: Article

References (30)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System 2007, IARC: Lyon, 4.
2. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 2010, 9:717-726. 10.1016/S1474-4422(10)70105-8, 3079431, 20610347.
3. Gomori E, Pal J, Kovacs B, Doczi T. Concurrent hypermethylation of DNMT1. MGMT and EGFR genes in progression of gliomas. Diagn Pathol 2012, 7:8. 10.1186/1746-1596-7-8, 3292961, 22264301.
4. Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH. Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diagn Pathol 2010, 5:18. 10.1186/1746-1596-5-18, 2859381, 20331873.
5. Habberstad AH, Gulati S, Torp SH. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas-an immunohistochemical study. Diagn Pathol 2011, 6:43. 10.1186/1746-1596-6-43, 3127815, 21609421.
6. Cavalla P, Schiffer D. Cell cycle and proliferation markers in neuroepithelial tumors. Anticancer Res 1997, 17:4135-4143.
7. Prayson RA. Cell proliferation and tumors of the central nervous system. Part 1: Evaluation of mitotic activity. J Neuropathol Exp Neurol 2002, 61:501-509.
8. Prayson RA. Cell proliferation and tumors of the central nervous system, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol 2002, 61:663-672.
9. Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 2006, 12:143-147. 10.1007/BF02893360, 16998593.
10. WHO Classification Tumours of the Nervous System 2007, Lyon: IARC, 4, WHO.
11. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992, 168:357-363. 10.1002/path.1711680404, 1484317.
12. Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 1997, 56:857-865. 10.1097/00005072-199708000-00003, 9258255.
13. Prayson RA. The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol 2005, 12:144-148. 10.1097/01.pap.0000163957.21409.52, 15900115.
14. Taran K, Sitkiewicz A, Andrzejewska E, Kobos J. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour. Pol J Pathol 2011, 62:84-88.
15. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999, 5:2121-2132.
16. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 2001, 27:305-313. 10.1046/j.0305-1846.2001.00333.x, 11532161.
17. Hunt DP, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, Laskey RA, Coleman N. Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br J Neurosurg 2002, 16:10-15. 10.1080/02688690120114174, 11928726.
18. Lind-Landstrom T, Habberstad AH, Torp SH. Proliferative activity and histopathological features in diffuse grade II astrocytomas. APMIS 2012, 120:640-647. 10.1111/j.1600-0463.2012.02881.x, 22779687.
19. Lind-Landstrom T, Habberstad AH, Sundstrom S, Torp SH. Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol 2012, 5:152-158. 3294229, 22400076.
20. Margraf LR, Gargan L, Butt Y, Raghunathan N, Bowers DC. Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas-an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol 2011, 13:767-774. 10.1093/neuonc/nor041, 3129272, 21653594.
21. Wojnar A, Kobierzycki C, Krolicka A, Pula B, Podhorska-Okolow M, Dziegiel P. Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. Folia Histochem Cytobiol 2010, 48:442-446.
22. Werynska B, Pula B, Muszczynska-Bernhard B, Piotrowska A, Jethon A, Podhorska-Okolow M, Dziegiel P, Jankowska R. Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res 2011, 31:2833-2839.
23. Hanna-Morris A, Badvie S, Cohen P, McCullough T, Andreyev HJ, Allen-Mersh TG. Minichromosome maintenance protein 2 (MCM2) is a stronger discriminator of increased proliferation in mucosa adjacent to colorectal cancer than Ki-67. J Clin Pathol 2009, 62:325-330. 10.1136/jcp.2007.054643, 18474544.
24. Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol 2001, 25:1204-1207. 10.1097/00000478-200109000-00013, 11688582.
25. Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer 2009, 100:1128-1134. 10.1038/sj.bjc.6604967, 2669983, 19293805.
26. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715.
27. Brat DJ, Prayson RA, Ryken TC, Olson JJ. Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 2008, 89:287-311. 10.1007/s11060-008-9618-1, 18712282.
28. Alison MR, Hunt T, Forbes SJ. Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut 2002, 50:290-291. 10.1136/gut.50.3.290, 1773123, 11839701.
29. Hall PA, Coates PJ. Assessment of cell proliferation in pathology-what next?. Histopathology 1995, 26:105-112. 10.1111/j.1365-2559.1995.tb00639.x, 7737657.
30. Schiffer D, Cavalla P, Chio A, Richiardi P, Giordana MT. Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol 1997, 34:31-35. 10.1023/A:1005755119526, 9210051.